Global Anti-Suicide Drugs Market
Anti-Suicide Drugs Market Size And Forecast
According to Verified Market Research, The Global Anti-Suicide Drugs Market was valued at USD 3.62 Billion in 2018 and is projected to reach USD 4.95 Million by 2026, growing at a CAGR of 3.98% from 2019 to 2026.
Global Anti-Suicide Drugs Market Outlook
One of the major driving factors for the market is the increasing suicidal rates around the globe. According to WHO, out of the total deaths that happened in 2017, around 1-1.5% accounted for suicides. Other factors contributing to the growth of the market are rising awareness about good mental health, changing, increased focus on research and development leading to the launch of novel anti-suicidal drugs. However, lack of effective therapies, abusive used of drugs leading to addiction and rising adoption of unapproved therapies are likely to cause hindrance in the market growth over the forecast period.
Global Anti-Suicide Drugs Market Competitive Landscape
The Global Anti-Suicide Drugs Market study report will provide a valuable insight with an emphasis on global market including some of the major players such as Pfizer, Inc., Johnson & Johnson, Eli Lilly, and Company, Allergan plc, GlaxoSmithkline plc, AstraZeneca plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx, Inc..
Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. It has large database which includes the latest content from renowned authors and publications worldwide. It also provides customized Data and Reports according to the need of the client.